GPCR-ligand complex structure within 4 months

May 2nd, 2017 Villigen, Switzerland – In collaboration with a major pharma company, leadXpro AG announced today the successful delivery of multiple GPCR structure determination milestones ahead of schedule. The first structures were provided within 4 months after signing the agreement and leadXpro’s partner is now leveraging the structural detail of eleven high-resolution GPCR-ligand co-structures in their drug discovery campaigns. Terms of the agreement and pharma partner were not disclosed, but include upfront and milestone payments associated with high-resolution co-structure endpoints.

Michael Hennig, leadXpro CEO said: “We have impressed our research partner with the unprecedented speed and success rate of delivering novel ligand-bound GPCR structures with a great variety of binding modes.

“While the time from gene to structure varies with the drug target, determining GPCR-ligand X-ray co-structures can take years to accomplish in top research institutes and requires deep knowledge and expertise. This success story validates our approach and membrane protein structure determination platform and serves as a great example for how we can quickly and efficiently impact drug discovery programs via collaborative research efforts with partner organizations”.

About leadXpro AG

leadXpro is a lead discovery company focusing on membrane protein drug targets. We are committed to the application of biophysical and structure-based methods for the discovery and optimization of next generation lead compounds. leadXpro’s technology platform enables structural determination of membrane proteins where classical crystallographic techniques fail, unlocking structure-based drug discovery for challenging targets. We capitalize on the knowledge regarding membrane protein structural biology and facilities of the Paul Scherrer Institute (PSI) with premium access to the synchrotron Swiss Light Source (SLS) and the Free Electron Laser (SwissFEL). Core expertise beyond X-ray include single particle cryo-electron microscopy (cryo-EM) and electron diffraction (ED). For more information, please visit .

leadXpro is a registered trademark in the EU, Switzerland, US and Canada.

Contact Information

leadXpro AG
Michael Hennig, Chief Executive Officer

+41 (0)79 770 97 24